BIAF
NASDAQ · Biotechnology
Bioaffinity Technologies Inc
$0.38
-0.09 (-18.98%)
Open$0.45
Previous Close$0.47
Day High$0.46
Day Low$0.33
52W High$13.50
52W Low$0.51
Volume—
Avg Volume257.0K
Market Cap3.33M
P/E Ratio—
EPS$-11.32
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+7,312.5% upside
Current
$0.38
$0.38
Target
$28.39
$28.39
$22.24
$28.39 avg
$33.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 23.32M | 608.9K | 644.1K |
| Net Income | -56,422,017 | -195,635 | -204,930 |
| Profit Margin | -242.0% | -32.1% | -31.8% |
| EBITDA | -38,098,376 | -176,028 | -183,952 |
| Free Cash Flow | — | -119,784 | -113,422 |
| Rev Growth | — | +18.5% | +20.2% |
| Debt/Equity | 0.11 | 1.28 | 1.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $250.82 | +0.83% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $417.84 | +0.40% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.14 | +1.67% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $516.44 | -1.77% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $805.97 | +1.00% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.12 | +1.42% | 35.2 | 28.41B |